Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients

Recruiting Phase 2 Phase 3 Interventional Study
Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Jikei University School of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patient who meets all of the following criteria and who has given informed consent. 1. Adults (18 years of age or older, regardless of the time since ICU admission) currently admitted to an intensive care unit\*. \*Includes high care units, where continuous monitoring is con…
Contacts

Tomoko Fujii, MD,PhD

+81 3 3433 1111

tofujii-tky@umin.net

CONTACT